The Ontario government is partnering with the federal government, the City of Toronto and Sanofi, a leading global biopharmaceutical and vaccines company, to expand its Ontario facility to meet growing demand for flu vaccines, boost Canada’s preparedness for future pandemics and create 300 high-quality jobs.
Ontario is investing $55 million through a performance-based loan, toward construction of Sanofi’s $925 million state-of-art vaccine facility to meet growing demand for flu vaccines, specifically for populations at greater risk of influenza. The company is also committing to an average of $79 million a year in research and development in Ontario or more than a half a billion dollars over the life of the agreement. Sanofi will also be leveraging leading scientists in the province, giving them the industrial research and development experience that is valuable to companies.
“This is a critical investment as it will create 300 high quality jobs and push Ontario toward becoming less reliant on others for the production of flu and potentially other vaccines,” said Premier Ford.
The investment will enable Sanofi to bulk manufacture Fluzone® High-Dose Quadrivalent Influenza Vaccine, a flu vaccine approved for people 65 years and older, at its historic Connaught site in Toronto. The facility will include industrial scale Formulation, Filling and Packaging, a key requirement for pandemic preparedness.
The project will result in the production of more flu shots in Canada, while strengthening Ontario’s biopharmaceutical industry, making the province a strong candidate for future vaccine production.
This new facility is a second large manufacturing mandate for Sanofi at this site. In 2018, Ontario and Sanofi announced another large bulk vaccine manufacturing facility focused on doubling the site’s capacity to produce childhood vaccines. Sanofi Pasteur, a subsidiary of French headquartered Sanofi, is Ontario’s largest brand name biopharmaceutical company.
